Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China

Published:2019-05-08 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Hou Xingyun,Wan Xu,Wu Bin

Funder

National Natural Science Foundation of China

Foundation of Shanghai Municipal Commission of Health and Family Planning

Merck KGaA

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. Development and validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from randomised trials.;Basu;Lancet Diabetes Endocrinol.,2017

2. Diabetes in China: a societal solution for a personal challenge.;Chan;Lancet Diabetes Endocrinol.,2014

3. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in health technology assessments: a systematic review of the literature from 2008 to 2013.;Charokopou;Curr. Med. Res. Opin.,2016

4. 2013 China guideline for prevention and treatment of type 2 diabetes.;Chin. J. Endocrinol. Metabol.,2014

5. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin.;Craig;Expert Rev. Pharmacoecon. Outcomes Res.,2001

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Bibliometric analysis of research on the utilization of nanotechnology in diabetes mellitus and its complications;Nanomedicine;2024-07-02

3. Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China;Advances in Therapy;2024-06-16

4. A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list;BMC Health Services Research;2024-05-01

5. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3